Niranjan Y. Sardesai, PhD
Dr. Sardesai founded Geneos after building Inovio Pharmaceuticals into a Phase III cancer and infectious disease immunotherapy company serving as its Chief Operating Officer. He held positions of increasing responsibility after joining the company in 2006 where he helped formulate the company’s product development and growth strategies and reorganized the company into a DNA vaccine and immunotherapies company. For Inovio, Dr. Sardesai drove multiple M&A and licensing transactions to consolidate key technologies, establish the corporate footprint, and develop its immunotherapies platform and product pipeline. He led the strategic out-licensing of Inovio’s pipeline products to secure major licensing deals totaling over $1 Bn with pharma partners.
Dr. Sardesai was previously the founder and President of NVision Consulting Inc., a firm providing strategic counsel to entrepreneurial life sciences companies. He served as Director of Research and Development at Fujirebio Diagnostics, Inc., where he oversaw the expansion of the company’s oncology portfolio. Products developed under his leadership include groundbreaking new tests for mesothelioma (MESOMARKTM), bladder cancer and a multi-marker test for ovarian cancer (HE4).
Dr. Sardesai received a PhD in Chemistry from the California Institute of Technology and a MBA from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He was awarded fellowships at the Scripps Research Institute and the Massachusetts Institute of Technology (MIT). Dr. Sardesai received his Bachelor and Master of Science degrees in Chemistry from the Indian Institute of Technology, Bombay. Dr. Sardesai has authored over 120 peer-reviewed manuscripts and was recognized by PharmaVoice magazine as one of the top 100 most influential and inspirational leaders across the life sciences industry (2015).
Joann Peters, MHA
Joann Peters joined Geneos after a successful 19-year career working in the Contract Research Organization (CRO) industry where she supported the growth strategy of companies and effectively led oncology focused study teams. She is bringing her strong oncology clinical operations experience to Geneos and will play a pivotal role in the company’s growth by leading the execution of the clinical and development strategy. She leads all facets of Geneos Clinical and Business Operations, providing oversight to clinical trials and implementing operations strategy and structure.
Prior to joining Geneos, Joann served in roles of increasing responsibility at PRA, Chiltern and INC Research. Most recently, Joann served as the Vice President of Clinical Operations and Project Delivery at Linical Accelovance. At Linical Accelovance, she held multiple leadership roles spanning global, operational and investigative site relationship responsibilities with a focus in immuno-oncology, solid tumor and hematology. She was responsible for the design and clinical implementation of 30+ protocols spanning Phase I-IV clinical studies and ensuring that projects were delivered effectively and with transparency.
Joann received her B.S. from Iowa State University in Dietetics and a Master’s in Health Care Administration at Webster University.
Presently Freddi is President of CFO’Brien Consulting, LLC, for which she provides executive level strategic and financial consulting services. Freddi has previously held the roles of Chief Financial Officer, Chief Operating Officer, Controller and Director of Financial Reporting and has been integral in the growth and financing of both private and public companies ranging from preclinical through commercial stage. Collaborating with the Genova Group, a boutique accounting advisory firm, Freddi leads the technical accounting and financial reporting functions of Geneos.
Freddi’s corporate experience includes senior leadership roles at several life sciences companies including Complexa Inc., Cerecor Inc., Cervilenz Inc., Cardiokine Inc., Barrier Therapeutics, Inc. and at Infonautics, Inc., a technology company. Freddi currently serves on the Board of Directors of TELA Bio, Inc., a publicly held commercial-stage medical technology company, where she also chairs the Audit Committee. She is also on the Board of Directors of MacroGenics, Inc., a publicly held biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, and she is Chair of the Audit Committee. Before specializing in life sciences and technology, Freddi spent over a decade in professional service accounting firms, including PricewaterhouseCoopers, where she was focused on high growth companies in multiple industries. She received her Bachelor of Arts degree in accounting from Rutgers University and is a Certified Public Accountant – Inactive.
Ildiko Csiki, MD, PhD
Dr. Csiki most recently served as the chief commercial research and development (R&D) officer at City of Hope, an NCI-designated leading cancer center, where she leads the development of a translational biotech-like R&D arm and oversees the research business development and the office of transfer and licensing functions. Previously, Dr. Csikiserved as the chief medical officer at Sensei Biotherapeutics, where she was responsible for the clinical strategy for the discovery and development of cancer immunotherapies. Prior to that, Dr. Csiki served as Vice of President of Immuno-Oncology Clinical Development at Inovio Pharmaceuticals where she led the advancement of Inovio’s DNA-based cancer immunotherapies. She also held clinical development lead roles at Merck responsible for pembrolizumab (Keytruda®) development in multiple indications as well as at GSK focused on multiple assets for various cancer programs. Dr Csiki began her post-graduate career at the University of Pennsylvania, Perelman School of Medicine as a tenure-track physician scientist in the Department of Radiation Oncology. She earned an M.D. and Ph.D. in cancer biology from the Vanderbilt University School of Medicine. Her postdoctoral training included an internship in Internal Medicine and residency in radiation oncology at Vanderbilt and subsequently, a Holman Pathway Research Fellowship. She is also a General Management Program graduate from the Wharton Business School with focus in strategic innovation and entrepreneurship.